Abstract
Topical therapy is an attractive approach for the treatment ofLeishmaniamajorcutaneous leishmaniasis (CL). WR279396, an expanded-spectrum aminoglycoside ointment, is now in phase 3 trials. Because the application of a cream is easier than the injection of pentavalent antimony, many patients with CL will likely be treated with WR279396 soon after the onset of a lesion. However, this new therapeutic approach may impair the acquisition of immunity. We evaluated the impact of early topical therapy on acquired immunity in an optimized mouse model ofL. major-induced CL. The efficacy of the WR279396 ointment in this model has been established previously. Acquired immunity was defined as the absence of lesions upon reinoculation of the same parasite isolate at a different skin site. Bioluminescence-based follow-up of luciferase-expressingL. majorloads was also performed. In this model, the control ofL. majorloads at the initial inoculation site and the acquisition of immunity are simultaneous (day 22 postinoculation). The clinical and parasitological efficacies of WR279396 applied as early as day 11 postinoculation, i.e., during theL. majormultiplication phase, did not impair the acquisition of immunity to a secondL. majorchallenge. This is reassuring from the perspective of the wide deployment of WR279396-based therapy in foci whereL. majoris endemic.

This publication has 26 references indexed in Scilit: